VBI Vaccines Overview
Latest ROE for VBI Vaccines: 1517.93% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow1517.93%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for VBIV is 1517.93%. That is above the Healthcare sector average of 21.67%. Investors often review this figure alongside VBI Vaccines's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, VBIV currently prints 1517.93% for ROE, while the sector average sits near 21.67%. That is roughly 6905.4% above the sector mean. Large gaps often invite a closer look at VBI Vaccines's growth, margins, and balance sheet.
Return on Equity shows how effectively VBI Vaccines converts resources into returns. At 1517.93%, VBIV may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VBIV's ROE (1517.93%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack VBI Vaccines's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
